OC LIFe aims to connect industry with entrepreneurs and strengthen the life sciences and medical technology communities.
Create connections that could last a lifetime.
The OC LIFe (Life Science Innovators Forum) is a monthly free event series focused on creating a collaborative environment that fosters connections between innovators in the life sciences industry.
To keep everyone safe and healthy, we are going virtual.
3:00 PM – Program begins
Current Trends in Venture Financing: Impact of COVID-19 & More
There is a lot of uncertainty about how COVID-19 will change the startup investment climate. Our special guest panel will share their perspective on the current global crisis and how they are approaching venture investments.
- Jason Skolnik, Partner, Wilson Sonsini (Corporate Finance)
- Frank Stonebanks, Founder, Managing Partner, Kickflip Bioventures
- Chris Garabedian, Chairman & CEO, Xontogeny
- Arye Lipman, General Partner, MarsBio
Presented in Partnership
Meet the Panelists
Jason Skolnik is a corporate and securities partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. His practice covers a broad range of general corporate and transactional matters, including mergers and acquisitions, venture capital financings, joint ventures, public offerings and disclosure matters, corporate finance, and corporate advisory work. Jason represents companies at all stages of their life cycle, from start-ups to public companies, in addition to venture capital and private equity firms. He represents companies in a wide variety of industries, including biotech, medical devices, and media and entertainment.
Twenty-five years of global executive operational and investment experience from sales to CEO in biotech, pharma, med tech, drug delivery & HCIT, including executive management, fund formation and deal structuring/execution, negotiating, domestic & global marketing, L&A, finance, sales, venture capital investing & senior advisory, in small start ups, mid size public companies, large Fortune 50 companies, universities, not for profits, domestic and international and the public sector.
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.
Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.
Chris serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues. Chris is also on the Board of Directors of MassBio and serves as a Senior Advisor for the Boston Consulting Group.
Arye is a General Partner at MarsBio, a seed stage venture fund based in Los Angeles, investing in deeptech and biotech companies. Arye holds a degree in Molecular and Cellular Biology from UCLA and serves as a board member and advisor for various life sciences startups and accelerator programs in Southern California, including Lab Launch, Larta Institute, Biocom, The L4b, and Armada Biosystems. Along with his partners at MarsBio, he launched a COVID-19 Task Force, supporting high impact efforts to address the pandemic, including diagnostics, vaccines, therapies, and devices.